- Home
- MKTW vs GNTA Comparison
MKTW vs GNTA Comparison
Compare MKTW & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | GNTA |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 34.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MKTW | GNTA |
|---|---|---|
| Price | $16.38 | $1.20 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 8.5K | ★ 3.0M |
| Earning Date | 02-27-2026 | 03-24-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | ★ $342,206,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.08 | $1.26 |
| 52 Week High | $21.74 | $10.00 |
Technical Indicators
Market Signals| Indicator | MKTW | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 38.80 |
| Support Level | $16.37 | $1.26 |
| Resistance Level | $16.28 | $1.70 |
| Average True Range (ATR) | 0.51 | 0.13 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 70.00 | 24.88 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.